GlassScriptPhysician profile
Donna S Childs
NPI 1295843910
$1,939.49
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $385 · 2021: $400 · 2022: $306.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $461.67 | 2019-2022 | |
| Lundbeck LLC | $256.56 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $234.14 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $215.35 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $158.71 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $137.03 | 2020-2022 | |
| Allergan, INC. | $129.23 | 2019 | |
| Vanda Pharmaceuticals INC. | $82.25 | 2019 | |
| Jazz Pharmaceuticals INC. | $71.42 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.44 | 2021-2022 | |
| Shire North American Group INC | $38.50 | 2019 | |
| Ironshore Pharmaceuticals INC. | $30.18 | 2019-2022 | |
| Bausch Health US, LLC | $26.87 | 2022 | |
| Corium, LLC | $26.54 | 2022 | |
| Adlon Therapeutics L.P. | $14.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Childs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.